Eterna Therapeutics Inc. (NASDAQ:ERNA) Short Interest Update

Eterna Therapeutics Inc. (NASDAQ:ERNA) was the recipient of a significant decrease in short interest in the month of May. As of May 31st, there was short interest totalling 47,700 shares, a decrease of 9.7% from the May 15th total of 52,800 shares. Based on an average daily volume of 7,600 shares, the short-interest ratio is presently 6.3 days. Approximately 1.7% of the shares of the stock are sold short.

Eterna Therapeutics Price Performance

ERNA traded down $0.03 during trading on Tuesday, reaching $1.94. The stock had a trading volume of 4,409 shares, compared to its average volume of 8,720. The firm has a market capitalization of $10.51 million, a price-to-earnings ratio of -0.46 and a beta of 4.42. Eterna Therapeutics has a 1-year low of $0.84 and a 1-year high of $2.99. The stock has a 50 day moving average of $2.00 and a two-hundred day moving average of $1.88. The company has a quick ratio of 0.79, a current ratio of 0.79 and a debt-to-equity ratio of 3.03.

Eterna Therapeutics (NASDAQ:ERNA) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($1.23) earnings per share (EPS) for the quarter. The business had revenue of $0.05 million during the quarter.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in Eterna Therapeutics by 30.6% during the 3rd quarter. Vanguard Group Inc. now owns 24,898 shares of the company’s stock valued at $54,000 after purchasing an additional 5,830 shares during the period. Sippican Capital Advisors raised its stake in Eterna Therapeutics by 92.3% during the 4th quarter. Sippican Capital Advisors now owns 54,050 shares of the company’s stock valued at $97,000 after purchasing an additional 25,950 shares during the period. Lake Street Advisors Group LLC acquired a new stake in Eterna Therapeutics during the 4th quarter valued at $933,000. Finally, Avidian Wealth Solutions LLC acquired a new stake in Eterna Therapeutics during the 1st quarter valued at $36,000. Institutional investors own 70.55% of the company’s stock.

About Eterna Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.